Zocdoc

+7%

est. 2Y upside i

HealthcareSeries D+

Rank

#2649

Sector

Digital Health / HealthTech

Est. Liquidity

~2Y

Data Quality

Data: Medium

Zocdoc offers moderate expected upside (~7.4%) over 2 years, but with high risk due to competitive threats and a large preference stack.

Last updated: July 3, 2026

Bull (15%)+59%

Exit at 8x forward revenue ($2.86B) driven by IPO window and strong network effects; common upside 59.1%.

Base (40%)+19%

Exit at 6x forward revenue ($2.15B) as multiple converges to public comp range; common upside 19.3%.

Bear (45%)-20%

Exit at 4x forward revenue ($1.43B) due to big tech competition compressing multiples; common upside -20.4% after preference overhang.

Est. time to liquidity~2.0 years

Preference Stack Risk

severe

Funding Intensity

3160%

Total funding of $569M represents 31.6% of entry valuation, creating a large preferred overhang that reduces common recovery in downside scenarios.

Dilution Risk

low

Company is profitable and likely cash-flow positive, making a dilutive raise within 24 months unlikely.

Secondary Liquidity

moderate

A tender offer at $2.3B in May 2026 provides recent secondary liquidity, though a regular market is not guaranteed.

Other — 81 roles

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on Zocdoc's data — designed to show you've done your homework.

1
“How does Zocdoc plan to defend against Amazon and Google entering the booking space?”
2
“What is the timeline for a potential IPO and how would it affect employee equity liquidity?”
3
“Can you explain the cap table structure and the impact of the $569M preferred stack on common stock?”

Our model estimates +7% upside. What do you think?

Anonymous. Do not share material non-public information.

Comments are reviewed before they appear publicly.

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.